Venous thromboembolic events (VTEs) are common in patients with cancer, and long-term anticoagulation with a low-molecular-weight heparin (LMWH) is recommended. The effectiveness of a direct oral anticoagulant (DOAC) compared with an LMWH for preventing recurrent VTE in patients with cancer was uncertain at the time the trial began.
